EHHADH and metabolic dysfunction-associated steatotic liver disease: Regarding fatty acid metabolism (Figure 3b), the predicted presence of 3-hydroxyacyl-CoA dehydrogenase, rubredoxin NAD reductase, and aldehyde dehydrogenase (NAD+) was significantly higher in severe MASLD.